Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure

Diabetic Medicine

Volumn 24, Issue 2, 2007, Pages 124-130

  Aspromonte, N ^a,e   Feola, M ^b   Milli, M ^c   Scardovi, A B ^a   Coletta, C ^a   Carbonieri, E ^d   Giovinazzo, P ^d   Di Giacomo, T ^a   Barro, S ^d   Rosso, G L ^b   Ceci, V ^a   Milani, L ^d   Valle, R ^d  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d Ospedale Civile   (Italy)

^e NONE   (Italy)

Author keywords

Brain natriuretic peptide; Congestive heart failure; Diabetes; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; HYPOTHESIS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; DIABETIC ANGIOPATHIES; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 33846646108     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02070.x     Document Type: Article

References (47)

1. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-950.
2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
3. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-2673.
4. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38: 421-428.
5. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-1020.
6. Burger AJ, Tsao L, Aronson D. Prognostic impact of diabetes mellitus in patients with acute decompensated heart failure. Am J Cardiol 2005; 95: 1117-1119.
7. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
8. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M et al. on behalf of the BRING-UP Investigators. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail 2003; 9: 192-202.
9. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin Chem Lab Med 2002; 40: 752-760.
10. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164: 1978-1984.
11. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005; 330: 625.
12. Schnabel R, Lubos E, Rupprecht HJ, Espinola-Klein C, Bickel C, Lackner KJ et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47: 552-558.
13. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G et al. Primary results of the rapid emergency department heart failure outpatients trial (REDHOT). J Am Coll Cardiol 2004; 44: 1328-1333.
14. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after discharge in heart failure patients. Circulation 2004; 110: 2168-2174.
15. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005; 48: 156-163.
16. Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005; 48: 149-155.
17. Verges B, Zeller M, Desgres J, Dentan G, Laurent Y, Janin-Manificat L et al. High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock. Eur Heart J 2005; 26: 1734-1741.
18. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004; 44: 1047-1052.
19. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of CHF. The Framingham study. N Engl J Med 1971; 285: 1442-1446.
20. Wu AH, Omland T, Duc P, McCord J, Nowak RM, Hollander JE et al. The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. Diabetes Care 2004; 27: 2398-2404.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10.
22. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43: 1590-1595.
23. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579.
24. Task Force for the the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
25. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104: 2996-3007.
26. Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart failure patients in the emergency department. Rev Cardiovasc Med 2003; 3: S41-S48.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
28. Valle R, Carbonieri E, Tenderini P, Zanella C, De Cian F, Ginocchio G et al. Proposed protocol for the ambulatory management of patients discharged with heart failure diagnosis: collaborative project Venice-HF. Ital Heart J Suppl 2004; 5: 282-291.
29. Biosite. TriageBNP Package Insert. San Diego, CA: Biosite Inc., 2002.
30. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367.
31. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-875.
32. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-279.
33. Bell D. Heart failure. The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-2441.
34. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57-64.
35. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-41.
36. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-641.
37. Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 2005; 11: 498-503.
38. Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004; 27: 1929-1935.
39. Feola M, Aspromonte N, Canali C, Ceci V, Giovinazzo P, Milani L et al. Prognostic value of plasma brain natriuretic peptide, urea nitrogen and creatinine in outpatients > 70 years of age with heart failure. Am J Cardiol 2005; 95: 705-709.
40. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK et al. Impact of diabetes on cardiac structure and function: The Strong Heart Study. Circulation 2000; 101: 2271-2276.
41. Piccini JP, Klein L, Gheorghiade M, Bonow RO. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 2004; 116: 64S-75S.
42. Valle R, Bagolin E, Canali C, Giovinazzo P, Barro S, Aspromonte N et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiogr 2006; 7: 40-44.
43. Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH. Screening for heart disease in diabetic subjects. Am Heart J 2005; 149: 349-354.
44. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003; 26: 2081-2087.
45. Bruch C, Gotzmann M, Stypmann J, Wenzelburger F, Rothenburger M, Grude M et al. Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure incremental prognostic value of QRS duration and a restrictive mitral filling pattern. J Am Coll Cardiol 2005; 45: 1072-1075.
46. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131-138.
47. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J 2005; 149: 744-750.